IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

June 1, 2022

Study Completion Date

October 30, 2022

Conditions
Advanced/Metastatic Hepatocellular Carcinoma
Interventions
DRUG

Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib

"Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name:M1-c6v1~Drug:Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names:SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib"

All Listed Sponsors
collaborator

Guangzhou Virotech Pharmaceutical Co., Ltd.

INDUSTRY

lead

Liang Peng

OTHER

NCT04665362 - IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | Biotech Hunter | Biotech Hunter